RxDoctor Payments Data

Megan McGavern, DO

Internal Medicine · Newport News, VANPI 1013095892

Payments from drug & device makers

$902in general payments, 2019–2025

Across 46 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$112
  • Lilly USA, LLC$92
  • Optinose US, Inc.$90
  • Boehringer Ingelheim$73
  • Shield Therapeutics Inc$70
  • AbbVie$65
  • plus $399 from 12 others

What the payments were for

  • Food & beverage$88198%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$254,473
Medicare patients
436
Services billed
6,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$184,422
JardianceEmpagliflozin147$181,049
TrulicityDulaglutide80$161,291
EliquisApixaban67$60,861
JanumetSitagliptin Phos/Metformin Hcl27$40,878
JanuviaSitagliptin Phosphate24$37,789
XareltoRivaroxaban31$35,641
MounjaroTirzepatide15$33,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$31,938
LinzessLinaclotide16$19,117
Diclofenac Sodium37$15,600
Breo ElliptaFluticasone/Vilanterol23$14,324
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$12,331
FarxigaDapagliflozin Propanediol14$9,370
Spiriva HandihalerTiotropium Bromide17$8,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$92$194,96495 claims
Novo NordiskOzempic$112$184,422138 claims
Boehringer IngelheimJardiance$73$181,049147 claims
MerckJanumet, Januvia$24$78,66751 claims
PfizerEliquis$65$60,86167 claims
GSKTrelegy Ellipta, Breo Ellipta$37$46,26356 claims
Johnson & JohnsonXarelto$13$35,64131 claims
AbbVieLinzess, Synthroid$65$23,07775 claims
AstraZenecaFarxiga, Symbicort$61$16,20931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →